Meeting
2023 ASCO Genitourinary Cancers Symposium
Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study.
Authors
Marijo Bilusic
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
Marijo Bilusic , NIcole J Toney , Renee Nicole Donahue , Fatima Karzai , Ravi Amrit Madan , Jeffrey Schlom , James L. Gulley , Priyamvada Rai , Cassie Due , Philip Gregory , Beatriz Mateo-Victoriano , Elizabeth R. Plimack , Daniel M. Geynisman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02614859
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 377)
DOI
10.1200/JCO.2023.41.6_suppl.377
Abstract #
377
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1).
First Author: Marijo Bilusic
Poster
2013 Genitourinary Cancers Symposium
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.
First Author: Bertrand Tombal
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2, multicenter, randomized study of salvage radiation therapy +/- metformin for recurrent prostate cancer after radical prostatectomy (SAKK 08/15 – GETUG-AFU 34 PROMET trial).
First Author: Alan Dal Pra